Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Collette

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|December 1, 2000
1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat proteinJ M Péloponèse, C Grégoire, S Opi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancerM M-Rabet, O Cabaud, E Josselin, et al.
Blood Cancer Journal|June 4, 2020
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility studyA Collignon, M A Hospital, C Montersino, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|December 1, 2000
1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat proteinJ M Péloponèse, C Grégoire, S Opi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancerM M-Rabet, O Cabaud, E Josselin, et al.
Blood Cancer Journal|June 4, 2020
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility studyA Collignon, M A Hospital, C Montersino, et al.
Pageof 4